We have developed a new method for assembling targeted nanoparticles that utilizes the complexation between targeting agents that contain
boronic acids and
polymer-
drug conjugates that possess diols. Here, we report the first in vivo, antitumor results of a nanoparticle formed via this new assembly methodology. A nanoparticle consisting of a
mucic acid polymer conjugate of
camptothecin (
CPT), MAP-
CPT, and containing on average one
Herceptin antibody is investigated in nude mice bearing HER2 overexpressing BT-474 human
breast cancer tumors. Nontargeted MAP-
CPT and antibody-containing MAP-
CPT nanoparticles of ca. 30-40 nm diameter and slightly negative zeta potential show prolonged in vivo circulation and similar biodistributions after intravenous tail vein
injections in mice. The maximum tolerated dose (MTD) of the nontargeted and
Herceptin-containing MAP-
CPT nanoparticles is found to be 10 and 8 mg of
CPT/kg, respectively, in mice. Mice bearing BT-474 human
breast tumors treated with nontargeted MAP-
CPT nanoparticles at 8 mg of
CPT/kg show significant
tumor growth inhibition (mean
tumor volume of 63 mm(3)) when compared to
irinotecan at 80 mg/kg (mean
tumor volume of 575 mm(3)) and
CPT at 8 mg/kg (mean
tumor volume of 808 mm(3)) at the end of the study.
Herceptin antibody treatment at 5.9 mg/kg results in complete
tumor regressions in 5 out of 8 mice, with a mean
tumor volume of 60 mm(3) at the end of the study. Mice treated with MAP-
CPT nanoparticles at 1 mg of
CPT/kg do not show
tumor inhibition. However, all mice receiving administrations of MAP-
CPT nanoparticles (1 mg of
CPT/kg) that contain on average a single
Herceptin molecule per nanoparticle (5.9 mg of
Herceptin equivalent/kg) show complete
tumor regression by the end of the study. These results demonstrate that the antitumor efficacy of nanoparticles carrying anticancer drugs can be enhanced by incorporating on average a single antibody.